Inclusion Criteria:
- IIA-IIIC phase esophageal squamous cell carcinoma confirmed by histopathology and immunohistochemistry.
- R0 resection has been performed at least before 4 weeks.
- ECOG PS score: 0-1 points.
- Estimated survival time: at least 12 weeks.
- No radiotherapy, chemotherapy or molecular targeted therapy before.
- Main organs are functional, which meet the following criteria:
Blood Routine:
HB≥90 g/L（No blood transfusion within 14 days）, ANC≥1.5×109/L, PLT ≥80×109/L. Biochemical examination： ALB≥30g / L（No blood transfusion within 14 days）, ALT<2ULN； AST<2ULN TBIL≤1.5ULN； Plasma Cr≤1.5ULN；
- Volunteer with signed informed consent form, good compliance and good follow-up cooperation.
- Patients who the investigator believws they can benefit.
Exclusion Criteria:
- Those who have had other malignant tumors in the past or at the same time.
- Pregnant or lactating women.
- Patients with grade-II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTC interval ≥ 450 ms) and cardiac dysfunction according to NYHA criteria III to IV. Cardiac color Doppler examination: LVEF (left ventricular ejection) Score) <50%.
- Have clear gastrointestinal bleeding concerns (such as local active ulcer lesions, fecal occult blood ++), and a history of gastrointestinal bleeding within 6 months.
- Have a history of mental illness or psychotropic substance abuse.
- Patients who have participated in other drug clinical trials within 4 weeks.
- According to the investigator's judgment, patients who are at a risk or have accompanying disease.
- Patients who believe that they are unsuitable for inclusion.